[go: up one dir, main page]

DeGiosio, 2023 - Google Patents

Functional Effects of Schizophrenia-Associated MAP2 Phosphorylation Events

DeGiosio, 2023

View PDF
Document ID
9638867441576835947
Author
DeGiosio R
Publication year

External Links

Snippet

Microtubules (MTs) support myriad aspects of neuromorphological development, which is thought to be altered in schizophrenia (SZ). Microtubule-associated protein 2 (MAP2) is a prominent regulator of neuronal MT assembly and organization. Diminished …
Continue reading at d-scholarship.pitt.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Similar Documents

Publication Publication Date Title
Koh et al. Eps15 and Dap160 control synaptic vesicle membrane retrieval and synapse development
van de Willige et al. Microtubule plus-end tracking proteins in neuronal development
McLean et al. α-Synuclein–enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons
Biederer et al. Regulation of APP-dependent transcription complexes by Mint/X11s: differential functions of Mint isoforms
Cotrufo et al. A signaling mechanism coupling netrin-1/deleted in colorectal cancer chemoattraction to SNARE-mediated exocytosis in axonal growth cones
Hsu et al. Functional characterization of the microtubule-binding and-destabilizing domains of CPAP and d-SAS-4
US9206231B2 (en) Small peptide modulators of potassium channel trafficking
Heo et al. RGS2 promotes formation of neurites by stimulating microtubule polymerization
US12031136B2 (en) Treatment for skeletal diseases caused by intracellular protein trafficking defects
CN113209303B (en) WWP1 degradation oncoprotein MUC1 inhibition tumor through lysosome approach and application thereof
DeGiosio et al. Differential regulation of MAP2 by phosphorylation events in proline‐rich versus C‐terminal domains
Niewiadomska et al. Cytoskeletal transport in the aging brain: focus on the cholinergic system
US20200230207A1 (en) Treatment of bone growth disorders
US12116611B2 (en) Method of treating intellectual disability, autism and epilepsy associated with an IQSEC2 mutation and for identifying medicaments for treating the same
DeGiosio Functional Effects of Schizophrenia-Associated MAP2 Phosphorylation Events
Xie et al. The interaction between KATNA1 and CRMP3 modulates microtubule dynamics and neurite outgrowth
US12403184B2 (en) Compositions and methods for treating neurodegenerative disroders
JP2022525325A (en) Methods for screening compounds for the treatment or prevention of polyQ-related neurodegenerative disorders
Sayas et al. Shaping the Brain by Neuronal Cytoskeleton: From Development to Disease and Regeneration
US20240352414A1 (en) Three-dimensional direct neuronal reprogramming to model alzheimer's disease in human neurons
Chan An Investigation of the Roles of FE65 Interactors in Neurite Outgrowth and APP Processing
Beccari The role of stathmin-2 in neurons: implications for degeneration and regeneration
Stockmann Functional analysis of microtubule-associated proteins and their effect on microtubule dynamics using advanced microscopy techniques
Baker et al. The Bicaudal-D/Egalitarian complex defines the specificity of cargo transport by Dynein
Gopinathan et al. The Chromatin Protein CFDP1 Activates TPX2 and Promotes Chromosomal Microtubule Nucleation and Spindle Assembly